Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide Read more about Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide
FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab) Read more about FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab)
Amgen To Present New Long-Term Repatha™ (Evolocumab) Data Analysis At ESC Congress 2015 Read more about Amgen To Present New Long-Term Repatha™ (Evolocumab) Data Analysis At ESC Congress 2015
Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) Read more about Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)
Amgen And University Of California, Berkeley Announce Multi-Year Partnership To Assist Cancer Patient Advocacy Organizations In Measuring Effectiveness Of Programs Read more about Amgen And University Of California, Berkeley Announce Multi-Year Partnership To Assist Cancer Patient Advocacy Organizations In Measuring Effectiveness Of Programs
Amgen Announces Appointment Of Fred Hassan To Board Of Directors Read more about Amgen Announces Appointment Of Fred Hassan To Board Of Directors
Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 Read more about Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57
Amgen Announces 2015 Third Quarter Dividend Read more about Amgen Announces 2015 Third Quarter Dividend
Amgen Announces Webcast of 2015 Second Quarter Financial Results Read more about Amgen Announces Webcast of 2015 Second Quarter Financial Results
Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma Read more about Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma
